CEACAM5 (Tusamitamab Biosimilar) Recombinant Monoclonal Antibody
-
貨號:CSB-RA005165MB3HU
-
規(guī)格:¥83486
-
其他:
產(chǎn)品詳情
-
產(chǎn)品描述:CEACAM5(Tusamitamab Biosimilar Antibody)重組單克隆抗體是一種靶向癌胚抗原相關(guān)細胞黏附分子5(CEACAM5),其別名為癌胚抗原抗體、CD66e抗體、CEA抗體等,對應多種數(shù)據(jù)庫編號及分子名稱。該抗體以重組人CEACAM5蛋白制備,具有高度特異性,種屬反應性經(jīng)驗證適用于食蟹猴(Cynomolgus)模型。 Tusamitamab Biosimilar Antibody作為靶向CEACAM5抗體,Tusamitamab的類似物,其臨床研究主要探索單藥或聯(lián)合化療、免疫檢查點抑制劑在晚期實體瘤中的療效與安全性,尤其關(guān)注CEACAM5陽性患者的治療響應及生存獲益。CEACAM5作為腫瘤相關(guān)抗原,在結(jié)直腸癌、胃癌、非小細胞肺癌等上皮源性腫瘤中高表達,是重要的治療靶點。Tusamitamab通過特異性結(jié)合CEACAM5,可阻斷其介導的細胞黏附與信號傳導,抑制腫瘤細胞增殖、侵襲及轉(zhuǎn)移,同時可能通過抗體依賴的細胞介導的細胞毒性作用(ADCC)和補體依賴的細胞毒性作用(CDC)增強抗腫瘤免疫應答。 該抗體憑借對食蟹猴的種屬交叉反應性,成為轉(zhuǎn)化醫(yī)學研究的關(guān)鍵工具。研究者可利用食蟹猴模型評估藥物的藥代動力學特征、組織分布及長期毒性,為臨床給藥方案設(shè)計提供數(shù)據(jù)支持。此外,在基礎(chǔ)研究中,該抗體可用于檢測CEACAM5在腫瘤細胞系及組織樣本中的表達水平,探究其在腫瘤發(fā)生發(fā)展中的分子機制,助力新型聯(lián)合治療策略的開發(fā)。其高特異性和重組表達特性也確保了實驗結(jié)果的穩(wěn)定性與可重復性,推動腫瘤靶向治療的基礎(chǔ)與臨床轉(zhuǎn)化研究進展。
-
Uniprot No.:
-
基因名:
-
別名:Carcinoembryonic antigen antibody; Carcinoembryonic antigen-related cell adhesion molecule 5 antibody; CD66e antibody; CEA antibody; Ceacam5 antibody; CEAM5_HUMAN antibody; DKFZp781M2392 antibody; Meconium antigen 100 antibody; OTTHUMP00000199032 antibody; OTTHUMP00000199033 antibody; OTTHUMP00000199034 antibody
-
反應種屬:Human
-
免疫原:Recombinant Human CEACAM5 protein
-
免疫原種屬:Homo sapiens (Human)
-
標記方式:Non-conjugated
-
克隆類型:Monoclonal
-
濃度:It differs from different batches. Please contact us to confirm it.
-
保存緩沖液:0.01M PBS,pH7.4
-
產(chǎn)品提供形式:Liquid
-
應用說明:Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity?> 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method. -
儲存條件:Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
貨期:In stock
-
用途:It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.
相關(guān)產(chǎn)品
靶點詳情
-
功能:Cell surface glycoprotein that plays a role in cell adhesion, intracellular signaling and tumor progression. Mediates homophilic and heterophilic cell adhesion with other carcinoembryonic antigen-related cell adhesion molecules, such as CEACAM6. Plays a role as an oncogene by promoting tumor progression; induces resistance to anoikis of colorectal carcinoma cells.; (Microbial infection) Receptor for E.coli Dr adhesins. Binding of E.coli Dr adhesins leads to dissociation of the homodimer.
-
基因功能參考文獻:
- Positive CEA mRNA in low rectal cancer is a factor that predisposes patients to a high risk for overall recurrence, especially for local recurrence. PMID: 28291565
- High carcinoembryonic antigen elevation is associated with recurrence in rectal cancer. PMID: 29774483
- CEA and CA19-9 are cancer antigens that are late markers of carcinogenesis, with significantly elevated serum concentrations in case of colon cancer with already developed metastases. Older age group of patient has significantly elevated levels of both antigens. Cancer was twice more common in men than in women. PMID: 25568506
- High CEA expression is associated with breast cancer metastasis. PMID: 29433529
- Pretreatment serum CEA levels over 30.02 ng/mL on behalf of worse characteristics and unfavourable tumor behavior, and a poor prognosis for a nearly doubled risk of mortality in gastric cancer patients. PMID: 29358864
- Elevation of CEA level was an independent risk factor for the poor prognosis of early gastric cancer. PMID: 29121872
- The elevation of serum CEA level was independent from the other tumor markers in hypohidrotic condition represented by acquired idiopathic generalized anhidrosis. PMID: 28295553
- Elevated CEA levels during targeted therapy may be a more sensitive predictor of explosive lung adenocarcinoma progression in patients harboring mutant EGFRs compared to traditional imaging methods. PMID: 28705152
- Increased CEA expression is associated with colorectal cancer. PMID: 28128739
- The detection of TK1 combined with that of cytokeratin-19 fragment (CYFRA21-1), CEA or NSE increased the diagnostic value of TK1 for lung squamous cell carcinoma, adenocarcinoma and small cell lung cancer, respectively. PMID: 29247745
- In patients with non-small-cell lung cancer treated with nivolumab, worse pretreatment performance status, and higher carcinoembryonic antigen were associated with inferior progression-free survival. PMID: 29277824
- To examine the relation of carcinoembryonic antigen (CEA) response with tumor response and survival in patients with (K)RAS wild-type metastatic colorectal cancer receiving first-line chemotherapy in the FIRE-3 trial comparing FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab PMID: 27234640
- This is the first population-based investigation of a large cohort of exclusively stage I rectal cancer patients providing compelling evidence that elevated preoperative CEA level is a strong predictor of worse overall and cancer-specific survival. PMID: 27067235
- Elevated levels of systemic IFNgamma and IL-6 implied that the CEACAM5-specific T cells had undergone immune activation in vivo but only in patients receiving high-intensity pre-conditioning. PMID: 28660319
- Combination of the two tumor markers, CEA and CYFRA21-1, is a predictive and prognostic marker of docetaxel monotherapy for previously treated NSCLC patients PMID: 28870944
- Patients with CEA-High stage I NSCLC have a higher risk of regional or systemic relapse and should be followed-up carefully. PMID: 28870949
- Postoperative CEA level >2.5 ng/ml is a predictor of distant metastasis and a negative prognostic factor for survival in rectal cancer patients who receive preoperative chemoradiotherapy and curative surgery. PMID: 27553616
- Data show that triple-negative breast cancer (TNBC) patients with pre-therapeutic serum high levels of both carcinoembryonic antigen (CEA) and cancer antigen 15-3 (CA15-3) had shorter overall survival (OS) and disease-free survival (DFS) rates than those in the low-level groups. PMID: 27561099
- Serum CEA level is not influenced by the presence of benign dominant biliary stricture or superimposed bacterial cholangitis in patients with primary sclerosing cholangitis. PMID: 27943017
- Preoperative-CEA was elevated (>/=5.0 ng/mL) in 73.6% of the colorectal cancer patients and remained elevated after surgery in 32.7% of the patients. Elevated postoperative-CA 19-9 (>/=50 U/mL) was observed in 9.5% of the patients. Neither elevated pre-CEA nor elevated pre-CA 19-9 was associated with relapse-free survival (RFS) but both elevated post-CEA and elevated post-CA 19-9 were associated with reduced RFS. PMID: 27664887
- the diagnostic sensitivity and specificity of serum reactive oxygen species modulator 1 were only 41.38% and 86.21%, respectively, with the cutoff value of 27.22 ng/mL. The sensitivity and specificity of pleural fluid carcinoembryonic antigen were 69.23% and 88.00%, respectively, at the cutoff value of 3.05 ng/mL, while serum carcinoembryonic antigen were 80.77% and 72.00% at the cutoff value of 2.60 ng/mL. PMID: 28459208
- Taken together, the results of our study identified CEACAM5 as a novel cell surface binding target of Middle East respiratory syndrome coronavirus that facilitates infection by augmenting the attachment of the virus to the host cell surface. PMID: 27489282
- Data show that carcinoembryonic antigen (CEA) modestly differentiated between mucinous and nonmucinous lesions, and amylase did not distinguish intraductal papillary mucinous neoplasms (IPMNs) from mucinous cystadenomas (MCAs). PMID: 26646270
- In this study, we detected the tumor marker carcinoembryonic antigen (CEA) using the QD-LFTS system, which allowed quantitative analysis in the range of 1-100ng/mL with an ideal detection limit of 0.049ng/mL. Thus, the system is suitable for detecting CEA in the clinically accepted range. We also detected 70 positive and 30 negative serum samples using the Handing system, which exhibited good specificity and sensitivity. PMID: 27825889
- As a proof-of-concept study, the constructed platform exhibits good specificity for CEA and the detection limit reaches as low as 8pg/mL (45 fM) with a wide linear range from 0.01 to 60ng/mL in the both cases PMID: 27886601
- Under the optimal conditions, the proposed immunosensor was used for the detection of CEA with wide dynamic range in the range from 5 fg/mL to 50ng/mL with a low detection limit of 2fg/mL (S/N=3). PMID: 27871047
- Relative CL intensity of all-in-one dual-aptasensor, operated with the competitive reaction of CEA and hemin in the presence of the dual aptamer, was exponentially decreased with the increase of CEA concentration in human serum PMID: 27875751
- Data indicate that serum tumor markers showed significant shorter 3-year progression-free survival (PFS) in higher levels compared to lower levels for S-CYFRA 21-1 (cytokeratin 19 fragment), S-SCCA and S-CEA. PMID: 26432331
- Multivariate logistic regression analysis revealed TC and DeltaCEA as independent factors in predicting TRG; TC showed a sensitivity of 62.79 %, a specificity of 91.49 %, a Youden index of 0.543, a cutoff value of 5.52, and an AUC of 0.800 compared with DeltaCEA (sensitivity 76.74 %, specificity 65.96 %, Youden index 0.427, and AUC 0.761). PMID: 26531721
- Data suggest that joint detection of receptor-binding cancer antigen expressed on SiSo cells (RCAS1) and carcinoembryonic antigen (CEA) can improve the diagnostic sensitivity and specificity. PMID: 26438059
- High CEA level is associated with Oral Squamous Cell Carcinoma. PMID: 27165212
- High CEA expression is associated with metastasis and recurrence in endometrial cancer. PMID: 26779635
- ZKSCAN3 appears to promote colorectal tumor progression and invasion. ZKSCAN3 may facilitate hepatic metastasis of CRC associated with CEA particularly in cases with CEA-producing tumor PMID: 27127149
- we evaluated the clinical performance of LOCItrade mark-based tumor marker assays CEA, CA19-9, CA15-3, CA125 and AFP in patients with gastrointestinal cancer and demonstrated their high diagnostic power PMID: 28011514
- High carcinoembryonic Antigen expression is associated with gastric cancer. PMID: 25124614
- High CEA expression is associated with Squamous cell carcinoma of the skin. PMID: 27039776
- Preparation of Au-polydopamine functionalized carbon encapsulated FeO magnetic nanocomposites and their application for ultrasensitive detection of carcino-embryonic antigen. PMID: 26868035
- Elevated Carcinoembryonic Antigen Levels are associated with Colon Cancer. PMID: 26759308
- Baseline serum CEA levels can serve as predictive factors for the treatment of EGFR-TKI in non-small cell lung cancer patients harboring EGFR mutations. PMID: 27072247
- BALF and serum NSE, CEA, and CYFRA21.1 elevated in lung cancer, which had prompt value for pathology, especially significant for BALF. PMID: 27072263
- Significant levels of CEA, CYFRA 21-1, NSE, and TSGF were detected in the serum. The amounts found were useful for diagnosing non-small cell lung cancer (NSCLC) patients who depended on the currently limited biomarker development. PMID: 27072222
- We conclude that patients with high preoperative serum CEA levels should have more intensive follow-up for detection of synchronous liver metastasis. PMID: 26756614
- Elevated CEA expression is associated with Gastric Cancer. PMID: 26620645
- CEA, NSE, CA125 and pro-GRP could serve as biomarkers for SCLC, and CEA and CYFRA21-1 could serve as biomarkers for NSCLC. Pro-GRP, CA125 and CEA were related to the clinical stages of lung cancer PMID: 26560853
- In this phase I/II study, 14 high-risk disease-free ovarian (OC) and breast cancer (BC) patients after completion of standard therapies were vaccinated with MUC1, ErbB2 and carcinoembryonic antigen (CEA) HLA-A2+-restricted peptides and Montanide. PMID: 26892612
- combined pre-chemoradiotherapy CEA and post-chemoradiotherapy CEA levels enable more accurate prediction of rectal adenocarcinoma prognosis PMID: 26962798
- ESCC patients with lower Cyfra21-1 and CEA, higher miR-7 and severe myelosuppression were much more sensitive to CRT. PMID: 26708917
- Cyst fluid CEA levels have a clinically suboptimal accuracy level in differentiating pancreatic mucinous cystic neoplasms from pancreatic nonmucinous cystic neoplasms. PMID: 26077458
- High carcinoembryonic antigen expression is associated with Colon Adenomas. PMID: 27100181
- Serum CYFRA21-1 and CEA can be used as prognostic factors of NSCLC patients. Combinative detection of the two indices will be more reliable. PMID: 26333429
顯示更多
收起更多
-
亞細胞定位:Cell membrane; Lipid-anchor, GPI-anchor. Apical cell membrane. Cell surface.
-
蛋白家族:Immunoglobulin superfamily, CEA family
-
組織特異性:Expressed in columnar epithelial and goblet cells of the colon (at protein level). Found in adenocarcinomas of endodermally derived digestive system epithelium and fetal colon.
-
數(shù)據(jù)庫鏈接:
Most popular with customers
-
-
YWHAB Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC, IF, FC
Species Reactivity: Human, Mouse, Rat
-
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC
Species Reactivity: Human
-
-
-
-
-















